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A health research ethics committee (REC) to deal with medical 
research involving humans was established at the University 
of the Witwatersrand, Johannesburg (Wits), in October 1966, 4 
months after publication of the seminal article on ethics and clini-
cal research by Beecher.1 This committee, the first in South Africa, 
has functioned continuously ever since. From 1966 to 2002 it was 
known as the Committee for Research on Human Subjects (Medi-
cal) and subsequently as the Human Research Ethics Committee 
(Medical) (HREC(M)). The Committee has United States Federal 
Wide Assurance (FWA No. 00001223) and has applied for reg-
istration with the newly formed National Health Research Ethics 
Council in South Africa; it is informally accepted by the South Af-
rican Medical Research Council (MRC) and the Human Sciences 
Research Council (HSRC). There are two other RECs at the Uni-
versity, one dealing with research in the humanities (since 1988) 
and the other with research involving animals (since 1975).
In time other South African universities and the Medical Re-
search Council established RECs during the 1970s and 1980s, fol-
lowed by the South African Medical Association and the pharma-
ceutical industry in the 1990s and the Human Sciences Research 
Council and the Department of Health in the new millennium.
Regarding health research, the policy at Wits is that all such 
research must be approved by the HREC(M) (http://web.wits.
ac.za/Research/Ethics). There are two routes for applications to 
the HREC(M). ‘General’ research is submitted to the University’s 
central Research Office to a full-time administrator who services 
the committee aided, when required, by a part-time staff mem-
ber who attends to the other two committees. The administrator 
collates application documents, circulates them to the HREC(M) 
members, keeps minutes of the general research part of the 
monthly meeting, handles queries, maintains the master database 
and prepares clearance certificates for the Chairs to sign. 
Applications for sponsored clinical trials are submitted to 
the Ethics Division of the Wits Health Consortium (WHC), which 
is a private ‘not for profit’ company within the Faculty of Health 
Sciences of the University. Here four full-time members of staff 
manage the extensive documentation required by Good Clinical 
Practice for the University, the Medicines Control Council, and in-
ternational bodies. They maintain the sophisticated database and 
tracking system, service a Protocol Review Committee and keep 
minutes of the clinical trial section of the monthly HREC(M) meet-
ing. Standard Operating Procedures are at http://www.witshealth.
co.za/ethics.  About 10 days before an HREC(M) meeting, a Pro-
tocol Review Committee (PRC) within the WHC Ethics Division 
examines the science and safety of a proposed clinical trial and 
whether this may be carried out in the State-funded academic hos-
pitals attached to the University (these hospitals have representa-
tion on this committee). The findings of the PRC are provided at 
the HREC(M) meeting. 
The HREC(M) consists of 33 members, 28 from within the Uni-
versity and five from external institutions (two are from a neigh-
bouring university, one is from a local church and two are from 
private sector entities). The members, all of whom are appointed 
in their personal capacity, encompass the following disciplines: 
anaesthesiology, bioethics, dentistry, education, bioethics, gy-
naecology, immunology, internal medicine, law, neurology, nurs-
ing, occupational health, paediatrics, physiology, physiotherapy, 
psychiatry, psychology, public health, radiation oncology, religion, 
speech therapy, social work and surgery. There is one Chair and 
four co-Chairs, all of whom have equal decision-making powers. 
Coincidentally, one member serves on the RECs of the MRC, Pal-
liative Care Society and Health Professions Council of South Af-
rica Human Rights and Ethics Committee and is Deputy Chair of 
the National Health Research Ethics Council, and two are on the 
Ethics Committee of the HSRC, one of whom is the Vice-Chair. 
Length of HREC(M) experience ranges from a few months to 34 
years with over half the members having at least 10 years of expe-
rience. Formal qualifications in bioethics are held by four members 
with two more completing postgraduate courses.
Monthly meetings are held from January through November on 
the last Friday of the month from 12h30 until the agenda is com-
pleted, usually around 17h30. Applications submitted by the 7th 
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of a month are considered in the same month. Applicants for gen-
eral research (all research except sponsored clinical trials) have 
to provide 23 hard copies of a completed four-page application 
form as well as informed consent documents; they are advised 
also to submit four copies of a full protocol, but this is optional. Ap-
plications for sponsored clinical trials provide the 23 copies of the 
application form plus four copies of the extensive documentation 
required by the national regulating authority, the Medicines Control 
Council (MCC), the equivalent of the United States Food and Drug 
Administration. 
About 2 weeks before a meeting members confirm by email 
who will be attending, after which one of the Chairs assigns two 
members to assess each application in depth; however, all mem-
bers receive copies of all application forms and informed consent 
documents. By mutual arrangement, the Chairs share the work-
load so that each application is also assessed by a Chair. For ret-
rospective clinical record reviews or secondary data analysis one 
Chair and one member provide a written summary assessment at 
the meeting, subdivided into those requiring discussion and those 
that may be approved at once if HREC(M) members agree – this 
speeds the meeting. 
  The monthly REC meeting is run in two sections. In the first, 
sponsored clinical trials are considered and serviced by staff from 
the Ethics Division of the WHC. This part of the meeting is closed 
except to HREC(M) members plus applicants and sponsors of a 
particular trial who may attend, or be asked to attend, when their 
application is considered. In the second part, general research 
is considered serviced by the University’s Research Office. One 
hour of this section of the meeting is open to anyone who wishes 
to attend and is accredited with the Health Professions Council 
of South Africa for the compulsory continuing education ethics 
points required for maintenance of a clinical licence. In addition, 
any applicant may request to attend, or be requested to attend, 
for the consideration of their application. At the meeting the asses-
sors verbally report on the applications they have evaluated, after 
which discussion is open to the committee. 
Throughout the research ethics committee world there are 
complaints that committee workloads are high and increasing. 
While there is some published information from the developed 
world about this, there is a lack of publications from developing 
countries.
This paper evaluates the workloads of the longest established 
HREC(M) in South Africa for the years 2003 and 2007. 
Methods
After clearance of the protocol by the HREC(M), information from 
the minutes of the HREC(M) meetings and database of the Ethics 
Division of the WHC was obtained and placed into a SAS data set 
for analysis with SAS for Windows (Version 9.1 SAS Institute Inc., 
Cary NC, USA).  
 The fate of each application was examined and classified into:
•   Approved – either at the first consideration or after revision.
•   Minor revision – here an HREC(M) member is assigned to help 
an applicant rectify minor points. Approval is given once accept-
able modifications have been made.
•   Major revision – the application needs to be resubmitted to the 
full HREC(M) after extensive changes.
•   Not approved – the application is not acceptable.
•   Withdrawn – an applicant chooses to withdraw the application.
•   Removed from the agenda – if after 3 months no revision has 
been submitted by an applicant it is taken off the agenda. It may 
be replaced on request.
Results
General research
There was a 26% increase in total applications from 439 in 2003 
to 553 in 2007. The percentage of applications from graduates 
increased from 75% in 2003 to 90% in 2007 with an accompanying 
decrease in applications from undergraduates from 25% to 10%. 
The numbers of applications per month for the two years exam-
ined are shown in Fig. 1. In both study years a typical number of 
applications considered at each meeting was between 40 and 50 
with a peak of 72 in March 2007. The beginning and end of the 
year were the busiest times. 
The outcomes of the general research applications are shown 
in Table I. At the initial HREC(M) meeting a quarter to a third were 
approved at once, around 60% required minor revisions, and ap-
proximately 10% needed major revision and resubmission or were 
not approved. Ultimately some 80% of applications were approved 
but almost 20% were removed from the agenda due to inaction by 
applicants.
Clinical trials
In 2003 applications for 102 clinical trials were processed com-
pared with 86 in 2007, a reduction of 16%. The numbers of appli-
cations per month are shown in Fig. 2. The pattern of applications 
was erratic from January through July, but thereafter the numbers 
in 2003 and 2007 showed some parallels.
Outcomes of applications are listed in Table II. A striking fea-
ture is that 17% of applications in 2003 required major revision or 
were not approved compared with no such decisions in 2007.    
Discussion
A great deal has been written on guidelines for research ethics 
committees (known as Institutional Review Boards (IRBs) in some 
countries) to follow in their functioning, but there is little on work-
load.
Background 
The University of the Witwatersrand, with a current total student 
enrolment of 25 000 was established in 1922. It has five Faculties 
containing 37 Schools and more than 30 research entities. The 
Faculty of Health Sciences comprises Schools of Anatomical Sci-
ences, Clinical Medicine, Oral Health Sciences, Pathology, Public 
Health, Physiology and Therapeutic Sciences. In most years 400 
undergraduate and 60 postgraduate degrees are awarded and 
there are some 500 health specialists in training (see web.wits.
ac.za/Academic/Health/Faculty/History.htm).
In keeping with the research ethics policy of the University the 
HREC(M) deals with health research and some social science re-
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search carried out in health establishments or dealing with health. 
All applications are evaluated by the full HREC(M); occasional ex-
pedited approval by an ad hoc decision of at least two Chairs is 
limited to ‘provisional approval’ of a project with good reason to 
begin and a sound balance of benefits and risks but is subject 
to ratification by the full HREC(M). A waiver from ethics review 
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Fig. 1. General research application numbers by month of 
application.
Fig. 2. Clinical trial application numbers by month of 
application.
TAble I. HReC(M) DeCISIOnS fOR geneRAl ReSeARCH
       Initial decision                 Final decision
           2003               2007                      2003                       2007
       N             %           N           %                   N           %           N           %
Approved    118            27         205          37          Approved  339         77  451          81
Minor revision    270            62         307          55 
Major revision      32             7           27            5 
Not approved      19             4           14            3         Not approved     17           4    14            3
Withdrawn        0          0             0            0         Removed   83         19             88          16
           from agenda
   Total     439         100         553        100           Total  439       100          553        100
TAble II. HReC(M) DeCISIOnS fOR SPOnSOReD ClInICAl TRIAlS       
       Initial decision                   Final decision
           2003               2007           2003          2007
       N            %           N           %       N           %     N           %
Approved     14           14           6             7           Approved   88          86    83          97
Minor revision     66           65         77           90 
Major revision       8             8          0              0 
Not approved     11            11          0              0          Not approved    11           11     0             0
Withdrawn      3              3          3              3          Removed      3            3             3             3
            from agenda
   Total   102        101        86          100           Total  102      100            86         100
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may be granted by an HREC(M) Chair for research not involv-
ing humans – for example when the research uses only microbial 
cultures or commercial cell lines or is desk-top analysis of public 
domain material. 
In common with elsewhere the workload of HREC(M) mem-
bers is additional to their normal duties and consists of detailed 
assessment of up to 10 protocols per monthly meeting, handling 
of queries, assisting applicants to write or rectify applications, and 
occasionally serving on ad hoc subcommittees. The latter deal 
with quality assurance reports on research sites produced by an 
independent auditor. Chairs have the same duties but in greater 
volume. 
Both international and local research ethics guidelines state 
that monitoring of ongoing research is a responsibility of research 
ethics committees. Sponsored clinical trials adhering to Good 
Clinical Practice norms are monitored through twice-yearly reports 
and, from time to time, on-site quality assurance inspections by 
an independent auditor appointed by the HREC(M). An unsolved 
problem is monitoring of general research, due to the high num-
bers of projects and movement of applicants. It can be estimated 
that some 1 500 projects need to be monitored annually (500 new 
projects per year which last for say 3 years), plus the additional 
new projects, which is an enormous workload. Currently a single-
page list of projects completed or ongoing in the year, plus a dec-
laration that all have ethics approval which has been adhered to, 
is what is being used.
Should an applicant find the outcome of an application unsat-
isfactory an appeal is made to the HREC(M) for reconsideration. 
Should the appeal outcome be unacceptable, an applicant may 
approach the Deputy Vice-Chancellor (Research), who may ar-
range an outside re-assessment. Should a grievance be declared 
between an applicant and the HREC(M) the National Health Re-
search Ethics Council may be involved in arbitration.
What is not often realised by applicants is that while health 
researchers in South Africa must adhere to a moral requirement 
to obtain informed consent, they also have a legal obligation, 
since informed consent is entrenched in the Bill of Rights (Section 
12(2)(c)) of the South African Constitution2 and the National Health 
Act requires ethics approval of human health research.3
Change in workload at Wits
The reason for the increase in general research workload is un-
clear but may be due to an increasing emphasis on staff research 
by the University. Why there is a reduction in clinical trials is also 
obscure. Perceptions are that sponsors may be shifting to other 
countries for reasons of cost and because of slowness in process-
ing projects through the Medicines Control Council. A pleasing 
change has been the improvement in quality of applications and 
often discussion of a proposed clinical trial with the REC before 
submission of an application. These are the reasons why no clini-
cal trials were refused in 2007.
Reported workloads elsewhere
Australia
In order to see what Australian RECs might learn from Western 
European and US experience Frew4 visited eight institutions, two 
each in England, France, the Netherlands and the USA; he es-
timated the number of new applications per year as 300 - 400 
per institution. Millar5 stated that two major teaching hospitals in 
Perth review 100 applications each per annum at one of which 
REC members have to look at 50 - 100 pages for each monthly 
meeting. Dodds,6 on the other hand, maintained that anecdotal 
evidence suggested 500 pages of reading per meeting and 764 
applications per annum at an un-named institution. 
Finland
A total of 666 applications at two university hospitals in Finland for 
the years 1992, 1994, 1996 and 1998 were studied by Keinonen 
et al.7 Of these 55% were approved, 14% were approved with ad-
visory comments, 22% were amended, 5% were pending and 3% 
were not approved. The main problems were with participant con-
sent and study design. 
France
Ducullier et al.8 reported their findings from a retrospective cohort 
of 976 protocols seen in 1994 in 25/48 French RECs. Of the pro-
tocols 31% were approved without modification and 57% needed 
modification (19% required a second modification). Forty-six per 
cent of the modifications were to information/consent documents. 
The mean workload per REC per year was 39 new protocols, 39 
revisions and 37 amendments. Each new protocol required 6 hours 
for the expert panel at the initial consideration and then 3.25 hours 
per revision. Administrators spent 4.5 hours initially, 4.5 hours per 
revision and 3.5 hours per amendment.
Japan
REC meetings in 80 medical schools and general hospitals with 
more than 300 beds from 1996 to 2002 increased in frequency 
accompanied by increasing workload and responsibility.9 Medical 
school REC meeting frequency per years increased from 3.6 to 
7.7 while cases discussed at each meeting increased from 5.7 to 
51.2. 
Spain
Dal-Re et al.10 evaluated 100 clinical trial applications at 50 hos-
pitals in 25 cities in Spain. Three per cent were not approved and 
97% were approved, just over a third of which had modifications. 
Mean committee size was 12 members.
United Kingdom
A questionnaire as well as local research ethics committee reports 
in the UK between 1991 and 1995 were used by Nicolson11 to de-
termine workloads. Replies obtained from 209 of 255 possible re-
sponders showed that applications processed ranged between 9 
and 447 per Local Research Ethics Committee (LREC); the high-
est numbers were in 12 teaching hospitals, which had >250 ap-
plications each. Mean numbers of applications increased steadily, 
as follows: 1991 – 57, 1992 – 73, 1993 – 102, 1994 – 107 and 
1995 – 123, indicating a doubling over the 5-year period. Aver-
age committee membership numbered 11, three of whom were lay 
members. Most amendments were to information sheets. 
Boyce12 studied 353 applications for 38 scheduled meetings of 
London multi-centre RECs during 1997 - 2000. The median number 
of committee members was 14 (range 11 - 16). There were some 
10 applications per meeting (range 3 - 14), four of which were new 
(range 0 - 8). Four per cent were approved at the first meeting, 
62% received conditional approval, 29% were deferred and 5% 
were not approved. In 85% of applications there were problems 
with information sheets and in 50% with study design. Only one 
decision required a vote, the rest were decided by consensus. 
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United States of America
Wagner et al.13 surveyed 109 IRBs at Veteran’s Affairs hospitals in 
the US; response rates were 73% for administrators and 59% for 
chairs. They termed all types of protocol reviews, including amend-
ments or re-certifications, as actions. Sixty-seven IRBs were arbi-
trarily classed as small (N=22, mean support staff 2.3), medium 
(N=22, mean support staff 2.6) or large (N=23, mean support staff 
5.6). Actions handled by the three categories and their estimated 
average costs were small 52 (3 - 151) US$2 781, medium 431 
(172 - 826) US$416, and large 2 676 (1 637 - 3 399) US$187. 
Costs were highest when there were less than 150 actions.
According to Brown et al.14 the IRB at the University of Texas 
Health Science Center at San reviewed 850 new or renewal appli-
cations each year at a cost of approximately US$100 000 or about 
US$100 per application.
Meaning of the study – workload itself
This article shows the heavy and increasing workload of the 
HREC(M) on which we serve. It also indicates a lack of published 
information on the experiences of other RECs. What is available is 
reported in many ways but, we believe, with a common thread of 
increasing load and costs.
What should a workload be? This question is like the proverbial 
‘how long is a piece of string’ ... as long as it needs to be. The only 
recommendation found is in the standard operating procedures of 
the UK National Research Ethics Service which states that RECs 
should have at least 10 meetings per year, each of which should 
have not less than 5 and not more than 10 applications for dis-
cussion.15 In our circumstances this is unrealistic since applicants 
would wait many months to have a proposal reviewed.
Is our workload likely to increase? Certainly, for several rea-
sons. Firstly, at a local level the total number of applications con-
sidered by the HREC(M) increased by 18% from 541 in 2003 to 
634 in 2007. Secondly, the strategic plan of our university requires 
an increase in research to be a ‘research-driven’ university.16 Third-
ly, at a national level, because of forthcoming changes in require-
ment for training clinical specialists, the HPCSA and the Colleges 
of Medicine will implement a requirement that a research project 
must be completed for specialist registration; it is estimated that 
this may increase applications to the HREC(M) by about 200 per 
year. The heavy workload, in turn, could negatively affect quality of 
review. 
Is one solution to increase the number of RECs in an institu-
tion to decrease workload per meeting? At first glance this is ap-
pealing, but such an action will increase strain on support staff, 
probably requiring hiring of more people, thereby increasing costs 
to an institution. Also, there is the problem of finding members to 
serve on RECs; the work must be done over and above normal 
service and teaching loads, which are high. The reason for hav-
ing a large committee (33 members) at our university is to ensure 
an adequate attendance at meetings – usually 12 - 18 – given 
the heavy workload of members. Also, the larger the number of 
members attending a meeting the lighter will be each individual’s 
detailed assessment load.
Obtaining diversity of skill and demographic representation is 
also difficult in spite of numbers of faculty staff wanting to serve on 
the committee. Representation is not just a local problem. Camp-
bell et al.17 described 2 898 faculty members on IRBs at 121 4-year 
medical schools in the USA. Of these 73% were male, 84% white 
(non-Hispanic), 4% Asiatic and 5% from under-represented minor-
ity groups, while 76% were medical graduates. 
If the number of RECs is increased to cope with increasing 
application numbers there will be a concomitant need to increase 
support staff servicing the committees, which in turn will increase 
costs to the employing institution. 
Another option might be to reduce the research types required 
to be approved by the HREC(M). This is not feasible, because 
institutions must comply with local and international ethical and 
legal requirements.3,18-21
What has helped reduce load on the four full-time academics 
who are HREC(M) co-Chairs at our university is that the Chair is a 
semi-retired academic who has been retained for three mornings 
per week for ethics consultation. A visit by one of the authors (PC-
J) to the REC secretariat in the medical faculty of McGill University 
in Montreal found that a semi-retired Vice-Chair is active in the 
same way for the same reason. 
Ideally members serving on RECs should have some relief 
from other duties to facilitate review of applications, which are be-
coming more complex as well as more numerous. This route was 
followed by Johns Hopkins University, where the IRB (REC) func-
tioning was restructured following the death of a healthy volunteer 
in a clinical study.22
Meaning of the study – decisions made 
The rates of approvals, revisions and non-approvals of general 
research made by the HREC(M) follow the same trends as in Fin-
land,7 France,8 Spain10 and the UK.12 What is as yet unknown is 
why 16 - 19% of applications are removed from the agenda without 
a firm conclusion. Perhaps applicants are discouraged by having 
to revise applications, perhaps they leave the institution, or maybe 
some research is being done without ethics approval. 
A pleasing observation is that no clinical trial applications were 
rejected in 2007 compared with 11% in 2003. This is probably due 
to more active discussion by applicants, clinical research organi-
sations and sponsors with Chairs before submission applications 
plus clear standard operating procedures available on line (see 
www.witshealth/ethics).     
Conclusions
This paper has shown an increasing workload for the HREC(M) of 
the University of the Witwatersrand between 2003 and 2007, with 
the likelihood of more increase. This trend follows international pat-
terns. Since it is a legal requirement in South Africa for research 
involving humans to have ethics review in advance,3 institutions 
will have to adapt to suit their individual circumstances. 
We are most grateful to the HREC(M) support staff in the Wits Re-
search Office and Ethics Division of the Wits Health Consortium who 
make the committee work possible and to all our colleagues on the 
Committee for their hard work and dedication to high research ethics 
standards. Particular thanks go to Professor Ames Dhai for construc-
tive comments on the manuscript and to Dr Alpa Chohan for establish-
ing the 2003 data set while she was a dental student on an elective in 
the Dental Research Institute.
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